12/06/2026
A major feature published this week in Israel Hayom highlights a groundbreaking medical shift: evaluating CAR-T therapy for severe autoimmune diseases. Israel is rapidly emerging as a global frontrunner in this next-generation immune-reset therapy, proving how scientific excellence intersects at the absolute frontier of medicine.
Repurposing a cellular platform that redefined oncology, these trials in leading Israeli academic centers are generating striking data for patients who have exhausted all standard treatments.
This milestone offers critical insights for the global clinical development community:
Platform Repurposing: Moving cellular therapies to immunology unlocks vast potential, positioning forward-thinking sponsors to capture an expanding market.
Strategic Hubs: Israeli institutions operate among the most experienced CAR-T autoimmune sites globally, offering a distinct advantage in investigator capability and data quality.
Operational Imperative: Managing these trials remains one of the most logistically intense assignments in clinical research today, requiring precise ex*****on where established guidelines do not yet exist.
Pharma Clinical (CRO)
Planning a complex cell or gene therapy program? Discover how to leverage Israelโs unique position as a scientific frontier, combined with our global operational standards, to advance your clinical pipeline.
Let's connect: www.pharmaclinical.co.il
To view the article, click here, page 14.
https://www.israelhayom.co.il/health/article/20713527